It's been an excellent year for Viking Therapeutics ( VKTX 4.30%), a mid-cap biotech company. Thanks to impressive mid-stage ...

The mega-blockbuster weight loss GLP-1 drug is now also approved to treat obstructive sleep apnea in adults with obesity, in ...

Last year's first quarter saw a flurry of biotech takeover deals, starting off with Johnson & Johnson (JNJ)/Ambrx, Merck (MRK)/Harpoon, GSK (GSK)/Aiolos and Novartis(NVS)/Calypso in early January.

Already established as cornerstone therapies in diabetes and obesity, GLP-1 receptor agonists have now cracked into the ...

In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...

There are more than 300 GLP-1Rs in an active stage of development, from industry giants and potential market disrupters.

VK2735 is a novel dual-agonist designed to target the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. This combination enhances metabolic benefits ...

The GLP-1 receptor agonists work by mimicking the GLP-1 hormone in the gut, and the dual agonists work by mimicking both the ...

Newer therapies for multiple conditions were major stories this year, but long-term HF survival gains seem to have vanished.

The nod, just months after topline results from SURMOUNT-OSA came out, makes it the first drug approved for this indication.

Dr Jagadish Hiremath, a public health intellectual, says, “The normalisation of GLP-1 agonists like Ozempic and Wegovy as ...

and the dual agonists work by mimicking both the GLP-1 and GIP hormones, which regulate blood glucose and appetite. In most cases, when people start on these medications, they are prescribed low ...